• PORTFOLIO
  • ABOUT US
  • TEAM
  • CHALLENGE NETWORK
  • INSIGHTS
  • PRESS
  • CONTACT
From Molecule to Medicine: Paul Weiss on Centanafadine’s Journey to FDA Approval

From Molecule to Medicine: Paul Weiss on Centanafadine’s Journey to FDA Approval

by Clarevia Team | Oct 6, 2026 | Perspectives

Most drug candidates never make it all the way to patients. For early-stage healthcare investors, seeing a therapeutic advance from an early scientific idea through clinical development, acquisition, FDA approval, and ultimately toward commercialization is especially...
John Neis on Building the Conditions for Innovation

John Neis on Building the Conditions for Innovation

by North Woods | Aug 5, 2026 | Perspectives

Recently named Chair-Elect of the NVCA, Clarevia Ventures’ Founding Partner reflects on venture capital, public policy, and the importance of having a Midwest voice at the national table. Venture capital has helped shape some of the most important companies in the...
Precision Medicine 2.0: Why Surgery Must Move Beyond “More” to “Right”

Precision Medicine 2.0: Why Surgery Must Move Beyond “More” to “Right”

by North Woods | Apr 28, 2026 | Perspectives

By Joe Amaral, Chief Medical and Scientific Officer, Clarevia When I first heard the term “precision surgery,” I, of course, thought it must have been coined by a non-surgeon who has never been in the operating room. Every surgeon believes they are being...
Precision Medicine 2.0: Why Diagnostics Must Move Beyond Detection

Precision Medicine 2.0: Why Diagnostics Must Move Beyond Detection

by North Woods | Mar 24, 2026 | Blog, Perspectives

By Jenni Le, Principal, Clarevia A patient suspected of sleep apnea used to spend the night in a lab, hooked up to sensors, trying to sleep in an unfamiliar environment, often producing a poor representation of a typical night. Today, that same patient can sleep in...
Precision Medicine 2.0: Why Therapeutics Must Move Beyond the Molecule

Precision Medicine 2.0: Why Therapeutics Must Move Beyond the Molecule

by North Woods | Mar 4, 2026 | Blog, Perspectives

By Paul Weiss, PhD, Partner at Clarevia In breast cancer, there was a moment when outcomes changed dramatically, but only for certain patients. Herceptin, an antibody therapy, was developed to target an overexpression of the HER2 protein. If a patient was...

Follow Us

  • Follow

Quick Links

Home

Portfolio

About Us
Team
Challenge Network
Insights
Press
Contact

Join the Clarevia Community!

indicates required
Copyright © 2026. Clarevia. All Rights Reserved.